GlassScriptPhysician profile
George Shunda
NPI 1346434909
$3,660.57
in general payments reported to CMS, 2019-2025
26 companies · $1,491 in 2025
The $1,491 reported for 2025 was more than what 90% of Corneal and Contact Management providers received nationally (typical 2025 total: $227).
See the full distribution for Corneal and Contact Management
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $437 · 2020: $168 · 2021: $326 · 2022: $407 · 2023: $353 · 2024: $479 · 2025: $1,491.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,305 · Entertainment: $18.21.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,304.77 |
| Entertainment | $18.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dompe US, INC. | $447.54 | 2022-2025 | Oxervate |
| Alcon Vision LLC | $391.97 | 2019-2025 | Tryptyr, Eysuvis, Rocklatan |
| Mallinckrodt Hospital Products INC. | $371.09 | 2023-2025 | Acthar |
| Tarsus Pharmaceuticals, INC. | $351.09 | 2024-2025 | Xdemvy |
| Rxsight INC | $201.87 | 2022-2025 | Rxsight Contact Lens, Rxsight Injector Cartridge, Rxsight Light Delivery Device (Ldd) |
| Bausch & Lomb Americas INC. | $179.97 | 2022-2025 | Miebo, Prolensa, Lotemax Sm |
| Ani Pharmaceuticals, INC. | $175.93 | 2025 | Purified Cortrophin Gel |
| Novartis Pharmaceuticals Corporation | $170.70 | 2019-2022 | |
| Oyster Point Pharma, INC. | $157.98 | 2022-2025 | Tyrvaya, Ryzumvi |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $155.06 | 2019-2021 | |
| Glaukos Corporation | $150.01 | 2021-2025 | Kxl System (Not Refurbished), Photrexa Viscous and Photrexa, Photrexa |
| Abbvie INC. | $146.43 | 2022-2025 | |
| Kala Pharmaceuticals, INC. | $130.23 | 2021 | |
| Shire North American Group INC | $127.98 | 2019 | |
| Sun Pharmaceutical Industries INC. | $93.53 | 2020-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harrow Eye, LLC | $84.08 | 2023-2025 | Vevye, Iheezo |
| Allergan, INC. | $67.23 | 2021-2022 | |
| Optos, INC. | $41.00 | 2020-2025 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Thea Pharma INC. | $38.72 | 2023-2025 | Iyuzeh |
| Johnson & Johnson Surgical Vision, INC. | $36.57 | 2023 | Tecnis Iol |
| Carl Zeiss Meditec USA, INC. | $36.54 | 2023 | Visumax |
| Alcon Research LLC | $32.66 | 2019 | |
| Ocular Therapeutix, INC. | $23.57 | 2019 | |
| Biotissue Holdings INC. | $16.89 | 2019 | |
| Apellis Pharmaceuticals, INC. | $16.80 | 2025 | Syfovre |
| Aerie Pharmaceuticals, INC. | $15.13 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Shunda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.